Navigation Links
Xennex Inc. Providing Satoris Inc. with Latest GeneCards(R) Tools for Characterization of Protein Biomarkers Associated With Neurological Conditions
Date:4/20/2009

actions, related drugs & compounds and direct links to cutting-edge research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and RNAi reagents. GeneCards was developed over the last 12 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel.

About Xennex

Founded in 2003, Xennex Inc. (http://www.xennexinc.com) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services.

Xennex' customers include many of the world's leading Biotech and Pharmaceutical companies and organizations dealing with intellectual property, located in North America, Europe and Japan. Xennex' products are used in hundreds of commercial and academic organizations by tens of thousands of users around the globe.

About Satoris

Founded in 2003 and based in Redwood City, California, Satoris, Inc. is a molecular diagnostics company focused on developing blood-based tests for Alzheimer's disease. For more information, see http://www.satorisinc.com.

    For further information, please contact:

    Xennex Inc.
    David Warshawsky, Ph.D.
    Chief Executive Officer
    Tel: +1 617 497 7774
    davidw@xennexinc.com

This release was issued through eReleases(TM). For more information, visit '/>"/>

SOURCE Xennex Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Japan Patent Office Licenses GeneCards(R) from Xennex, Inc.
2. Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies
3. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
4. BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
6. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
7. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
8. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
9. Care to Care Begins Providing Radiology Benefit Management Services to Touchstone Health
10. Halogen Advances its Lead in Providing Employee Performance and Talent Management Solutions for the Healthcare Market
11. Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Follow us on LinkedIn –Cholesterol ... cholesterol carrier or lipoprotein in the blood. Such tests ... in the body, especially along the walls of blood ... other cardiovascular disorders. Cardiovascular Diseases (CVD) is the leading ... on a regular basis, to assess an individual’s risk ...
(Date:9/30/2014)... 2014 CORD:USE Cord Blood Bank – ... has entered into an Equity and Exclusive Services Agreement ... series of patented technologies for the isolation of human ... Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that ...
(Date:9/30/2014)... 30, 2014 Genedata, a ... drug discovery and related life science research, ... chosen Genedata Selector as its host-pathogen data ... FUNGITECT is a European consortium dedicated to ... via individualized anti-fungal drug therapies. Genedata Selector ...
(Date:9/30/2014)... 30, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... Office (USPTO) issued U.S. Patent No. 8,816,083 to ... Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates ... Thereof." The patent, which extends through ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... , ST. LOUIS, Aug. 7 KV Pharmaceutical Company ... owners of the Company,s Class A and Class B Common Stock, ... by written consent purported to have been taken by such Reporting ... of the Company,s By-Laws and is therefore invalid and not effective. ...
... , , BOTHELL, Wash., Aug. ... today reported financial results for the three and six months ended ... Bruce Morra, SCOLR Pharma,s President and CEO, said, "We continue to ... controlled release ibuprofen. These potential partners have been committing resources to ...
... , , , , ... 2Q09 Corporate Highlights: , , ... treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination ... agreement with Astellas Pharma Europe Ltd. (Astellas) for commercialization of Qutenza in Europe, ...
Cached Biology Technology:KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 2KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 3KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 4KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 5KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 6SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 8NeurogesX Reports Second Quarter 2009 Results 2NeurogesX Reports Second Quarter 2009 Results 3NeurogesX Reports Second Quarter 2009 Results 4NeurogesX Reports Second Quarter 2009 Results 5NeurogesX Reports Second Quarter 2009 Results 6NeurogesX Reports Second Quarter 2009 Results 7NeurogesX Reports Second Quarter 2009 Results 8NeurogesX Reports Second Quarter 2009 Results 9NeurogesX Reports Second Quarter 2009 Results 10NeurogesX Reports Second Quarter 2009 Results 11NeurogesX Reports Second Quarter 2009 Results 12
(Date:9/30/2014)... to know what goes wrong with your muscles because of ... what "normal" actually is. That,s where a new research report ... FASEB Journal comes in. In the report, a ... molecules that can help scientists "see" which genes are active ... found never-before-detected gene activity and that men have approximately 400 ...
(Date:9/30/2014)... Sept. 30, 2014  Spectra Automation, a ... the biotech and power generation industries, announced ... Bioprocess Manager, an easy-to-use and cost-effective data ... bioprocess development laboratories. Most ... and analyzer systems. Accessing and consolidating data ...
(Date:9/30/2014)... Winners of The Economist,s prestigious Innovation awards 2014 will ... at the JW Marriott Hong Kong on Friday, October 10 th ... experiences and the lessons those hold for others. The awards, which ... past decade, will be presented at a ceremony in ... be the first time the ceremony has come to ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... try savoring the scent of lemon, mango, lavender, or ... first scientific evidence that inhaling certain fragrances alter gene ... stress levels. Their study appears in ACS, Journal ... In the new study, Akio Nakamura and colleagues ...
... Applying biological molecules from cell membranes to ... on the very basics of cell-to-cell interaction. ... Oregon biophysicist and colleagues suggest that putting lipids ... could lead to new classes of self-assembling materials ...
... allows farmers to harvest rice earlier, giving them more time ... and ease hunger during monga -- the hunger months. ... from September to November after the previous season,s food has ... December. According to the Bangladesh Bureau of Statistics, ...
Cached Biology News:New windows opened on cell-to-cell interactions 2New windows opened on cell-to-cell interactions 3Early rice harvests ease annual famine in Bangladesh 2
... Lambda Protein Phosphatase ( ... protein phosphatase with activity ... and tyrosine residues. It ... product of the ORF221 ...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
Oven mesh sheets, large, 23 x 23cm, pack of 5...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
Biology Products: